Selank Research: Mechanism, Models & Sourcing

What is Selank?

Selank (sometimes designated TP-7) is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its design derives from tuftsin, an endogenous immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg), to which additional residues were added in an effort to extend metabolic stability in research settings. In the literature, Selank is most often described as a tuftsin analog and is classified among regulatory peptides examined for activity in the central nervous system.

Reviews of the molecule (for example, summaries of its biological activity indexed in PubMed) frame Selank as a tool compound used to probe peptide-mediated signaling in neuropharmacology models. VANTA supplies Selank strictly as a reference material for in-vitro and preclinical laboratory research. Nothing here should be read as describing use in humans.

Studied mechanisms

Several mechanistic hypotheses appear repeatedly in the Selank literature. One frequently cited line of work examined Selank as an inhibitor of enkephalin-degrading enzymes; researchers reported in cell-free and plasma assays that the peptide slowed enzymatic hydrolysis of enkephalins, which authors proposed as one possible contributor to its observed activity in animal models.

A second body of work has examined gene-expression effects. In-vitro studies in neuroblastoma-derived cell lines reported that Selank exposure was associated with changes in the expression of genes involved in GABAergic neurotransmission, in some experiments paralleling changes seen with GABA itself. These are associations described in controlled laboratory systems and are presented here only to characterize the research literature, not to imply any functional outcome.

Research models and findings (hedged)

Preclinical reports on Selank span rodent behavioral paradigms, in-vitro cell models, and analyses of peripheral biochemical markers. In animal-model studies, investigators have examined Selank in the context of stress-reactivity and behavioral assays, often measuring downstream biochemical endpoints such as plasma enkephalin-degrading enzyme activity rather than behavior alone.

Separately, neurotrophic-factor studies in rodents have reported that intranasal Selank administration was associated with altered expression of brain-derived neurotrophic factor (BDNF) in hippocampal tissue at the mRNA and protein level within defined time windows. A clinical-pharmacology comparison published in the Russian neurology literature also examined Selank against a benzodiazepine comparator in anxiety-disorder cohorts. These findings are reported as observed in their respective experimental systems; they are not claims about safety or efficacy, and outcomes in any model do not generalize to human use.

Handling and reference characteristics

In published protocols, Selank is typically handled as a lyophilized peptide reconstituted in an appropriate aqueous solvent for laboratory work, with researchers accounting for peptide solubility, pH, and storage temperature to preserve integrity. Like many short peptides, it is generally described as sensitive to repeated freeze-thaw cycles and prolonged exposure to ambient temperature.

VANTA documents the molecular formula, sequence, and net peptide content on accompanying paperwork so that receiving laboratories can reconcile the material against their own analytical references before designing experiments. All such handling notes are intended for trained personnel working in controlled research environments.

How VANTA verifies it

Every VANTA Selank lot is characterized before release. Identity is confirmed by mass spectrometry, which checks the measured molecular mass against the expected value for the heptapeptide sequence. Chromatographic purity is assessed by reversed-phase HPLC, with the purity percentage and the corresponding chromatogram recorded for the lot.

These results are compiled into a per-batch Certificate of Analysis (COA) that ships with, or is made available for, the specific lot supplied. This documentation lets a laboratory verify that the reference material matches its stated identity and purity specification. VANTA provides this material for research-use-only purposes; it is not for human or veterinary use, and no diagnostic, therapeutic, or consumption claims are made.

Selank: A Research Reference Overview